 |
BioWorld-International-2011-09-07
Amakem Gets $25M for Kinase Inhibitors for Ophthalmology
Amakem Gets $25M for Kinase Inhibitors for Ophthalmology
In what may well be the largest Series A round in European biotechnology this year, Amakem NV raised €18 million (US$25.6 million) to fund development of a series of locally acting kinase inhibitors aimed at ophthalmology indications. (BioWorld International)